ProCE Banner Activity

Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results

Slideset Download
Conference Coverage

Adding the PI3K inhibitor parsaclisib to ruxolitinib reduced spleen volume and improved symptom burden in patients with myelofibrosis and an inadequate response to ruxolitinib.

Released: December 14, 2022

Expiration: December 13, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen